Analysis characterizes clinical and genetic traits in recurrent ovarian cancer patients undergoing PARP inhibitor therapy, indicating complex management needs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Glajzer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: